Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,778 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director directly owned 2,778 shares of the company’s stock, valued at $326,553.90. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Simon Read also recently made the following trade(s):

• On Monday, August 10th, Simon Read sold 2,777 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $109.55, for a total transaction of $304,220.35.

Dianthus Therapeutics Price Performance

DNTH stock traded down $1.84 on Wednesday, reaching $113.70. 793,226 shares of the company were exchanged, compared to its average volume of 959,581. The firm has a market capitalization of $6.22 billion, a PE ratio of -27.40 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 12 month low of $22.06 and a 12 month high of $117.88. The stock’s fifty day moving average price is $98.77 and its 200 day moving average price is $83.98.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, research analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $27,000. First Horizon Corp bought a new stake in Dianthus Therapeutics in the first quarter valued at about $32,000. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics in the fourth quarter valued at about $40,000. EFG International AG acquired a new position in Dianthus Therapeutics in the second quarter worth about $49,000. Finally, Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics in the third quarter worth about $64,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analysts Forecast Growth

DNTH has been the subject of several research reports. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. HC Wainwright upped their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial reissued a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.